medigraphic.com

2014, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2014; 52 (1)

Blood and urine lead levels in children with attention deficit hyperactivity disorder

Sánchez-Villegas MCS, Cortés-Vargas A, Hidalgo-Luna RG, Alam-Escamilla DA, Vargas-García VM, Loría-Castellanos J

Language: Spanish
References: 21
Page: 21-27
PDF size: 126.77 Kb.


ABSTRACT

Background: attention deficit hyperactivity disorder is the most common neuropsychiatric disorder in children; symptoms can persist into adult life by 60 %. Our objective was to quantify the levels of lead in blood and urine in pediatric patients with attention defi cit hyperactivity disorder.
Methods: we did an observational study which included a captive population of children diagnosed with attention deficit hyperactivity disorder in the mental health service of Hospital General, from Centro Médico Nacional La Raza. Lead levels were determined in blood and urine by atomic absorption technique.
Results: we included 39 patients, 932 % male, with a mean age of 9.2 ± 2.16 years. The deficit and hyperactivity disorder combined type was the most frequent (69.2 %); 49 % of patients were found with toxic lead levels in blood (above 10 mg/dL); 17.9 % with stage III and 5.12 % with stage IV, according to the Mexican Offi cial Standard (NOM-199-SSA-2000). Signifi cant association was found between blood lead levels and the clinical expression of attention defi cit hyperactivity disorder.
Conclussions: levels of lead exposure during early childhood have been shown to be inversely proportional to neurological development in the first seven years of life. Data results are insuffi cient to relate them with causality.


REFERENCES

  1. Ulloa RE, Arroyo E, Ávila JM, Cárdenas JA, Cruz E, Gómez D, et al. Algoritmo del tratamiento para el trastorno por défi cit de atención con hiperactividad en niños y adolescentes. Salud Mental. 2005;28(5):1-10. Texto libre en http://www.redalyc.org/pdf/582/58252801.pdf

  2. Poza-Díaz MP, Valenzuela-Moreno MV, Becerra- Alcántara D. Guía clínica. Trastorno por défi cit de atención e hiperactividad. México: Secretaría de salud; s/a. Disponible en http://www.sap.salud.gob. mx/downloads/pdf/nav_guias1.pdf

  3. Fernández-Jaén A. Trastorno por défi cit de atención e hiperactividad y retraso mental. Rev Neurol. 2006;42(Supl 2):S25-7.

  4. Nigg TJ, Knottnerus GM, Martel MM, Nikolas M, Cavanagh K, Karmus W, et al. Low blood lead levels associated with clinically diagnosed attention-defi cit/ hyperactivity disorder and mediated by weak cognitive control. Biol Psychiatry. 2008;63(3):325-31. Texto libre en http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2818788/pdf/nihms172956.pdf

  5. Nigg TJ, Nikolas M, Knottnerus GM, Cavanagh K, Friederici K. Confi rmation and extension of association of blood lead with attention-defi cit/hyperactivity disorder (ADHD) and ADHD symptom domains at population-typical exposure levels. J Child Psychol Psychiatry. 2010;51(1):58-65. Texto libre en http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC2810427/ pdf/nihms140374.pdf

  6. Norma ofi cial mexicana NOM-199-SSA1-2000, salud ambiental. Niveles de plomo en sangre y acciones como criterios para proteger la salud de la población expuesta no ocupacionalmente. México: Secretaría de Salud; Diario Ofi cial de la Federación del 18 de octubre de 2002.

  7. Goldfrank LR, Hoffman RS, Nelson LS, Howland MA, Lewin NA, Flomenbaum NE. Goldfrank’s manual toxicologic emergencies. New York: McGraw-Hill; 2007.

  8. Garza A, Chávez H, Vega R, Soto E. Mecanismos celulares y moleculares de la neurotoxicidad por plomo. Salud Mental 2005;28(2):48-58. Texto libre en http://www. fi sio.buap.mx/online/DraVegaR/2005%20Garza%20 y%20Cols,%20Salud%20Mental%20-%20 Plomo.pdf

  9. Padilla-Magunazelaia A, Rodríguez-Sierra N, Martínez- Castillo A; Grupo de Trabajo de Salud Laboral de la Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Protocolos de vigilancia sanitaria específi ca. Plomo. Madrid: Ministerio de Sanidad y Consumo; 1999. Texto libre en http://www.zerbitzu-orokorrak.ehu.es/p258- shprevct/eu/contenidos/informacion/sp_legislacion/eu_ leg_upv/adjuntos/PLOMO.pdf

  10. Haddad LM, Shannon MW, Winchester JF, editores. Clinical management of poisoning and drug overdose. Third edition. Philadelphia: Saunders; 1998.

  11. Handal-Silva A, Morán-Raya C. Toxicología del plomo. En: Handal-Silva A, Morán-Raya C, editores. Tópicos selectos de toxicología de la reproducción. México: Benemérita Universidad Autónoma de Puebla; 2009.

  12. Ortega-García JA, Ferrís-Tortajada J, Cánovas-Conesa A, García-Castell J. Neurotóxicos medioambientales (y II). Metales: efectos adversos en el sistema nervioso fetal y postnatal. Acta Pediatrica Esp. 2005;63:182-92. Texto libre en http://www.pehsu. org/wp/pdf/neurotoxicos2.pdf

  13. Wang HL, Chen XT, Yang B, Ma FL, Wang S, Tang ML, et al. Case-control study of blood lead levels and attention defi cit hyperactivity disorder in Chinese children. Environ Health Perspect. 2008;116(10):1401-6.

  14. Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. Exposures to environmental toxicants and attention defi cit hyperactivity disorder in U.S. children. Environ Health Perspect. 2006;114(12):1904-9.

  15. Froehlich TE, Lanphear BP, Auinger P, Hormung R, Epstein JN, Braun J, et al. Association of tobacco and lead exposures with attention-defi cit/hyperactivity disorder. Pediatrics. 2009;124(6):e1054-63. Disponible en http://pediatrics.aappublications.org/ content/124/6/e1054.full.html

  16. Roy A, Bellinger D, Hu H, Schwartz J, Ettinger AS, Wrigth RO, et al. Lead exposure and behavior among young children in Chennai, India. Environ Health Perspect. 2009;117(10):1607-11. Texto libre en http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC2790517/pdf/ ehp-117-1607.pdf

  17. González-Valdez E, González-Reyes E, Bedolla- Cedeño C, Arrollo-Ordaz EL, Manzanares AE. Niveles de plomo en sangre y factores de riesgo por envenenamiento de plomo en niños mexicanos. Rev Fac Ing Univ Antioquia. 2008;43:114-9. Texto libre en http://ingenieria.udea.edu.co/grupos/revista/revistas/ nro043/114-119.pdf

  18. Diamond J, Matsson A. Trastorno por défi cit de atención/ hiperactividad. En: Parmelee DX, editor. Psiquiatría del niño y del adolescente. Segunda edición. Barcelona: Harcout Brace; 1998.

  19. Sanders T, Liu Y, Buchner V, Tchounwou PB. Neurotoxic effects and biomarkers of lead exposure: a review. Rev Environ Health. 2009;24(1):15-45.

  20. Eubig PA, Aguiar A, Schanz SL. Lead and PCBs as risk factors for attention defi cit/hyperactivity disorder. Environ Health Perspect. 2010;118(12):1654-67.

  21. Aguiar A, Eubing PA, Schantz SL. Attention defi cit/hyperactivity disorder: a focused overview for children’s environmental health researchers. Environ Health Perspect. 2010;18(12):1646-53. Texto libre en http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC3002183/pdf/ ehp-118-1646.pdf




2020     |     www.medigraphic.com